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persists for up to a year (Judd et al., 1998), significantly impairing 
the health and daily activities of the afflicted (Manji et al., 2001). In 
fact, the net loss of productivity stemming from the disorder costs 
the United States an estimated 83 billion dollars each year(Coyne 
et al., 1994). Even with the best FDA-approved antidepressant treat-
ments, the majority of MDD patients will inevitably suffer from 
multiple depressive episodes during their lifetime(Mueller et al., 
1999; Kessler et al., 2003). To make matters worse, each recurrent 
depressive episode puts the patient at a 16% increased risk for 
developing an additional depressive episode during their lifetime 
(Solomon et al., 2000). More efficacious and durable antidepressant 
treatments are needed.
Despite considerable efforts to improve pharmaceutical-based 
antidepressant treatment efficacy, 50–60% of all depressed patients 
remain partially or fully unresponsive to a first course of properly 
prescribed therapy (Fava, 2003). Up to 20% of these patients require 
more extreme treatment measures, employing multiple antide-
pressant  medications  and/or  electroconvulsive  therapy  (ECT) 
with variable success rates (Fava, 2003; Mayberg et al., 2005). The 
low acute response rate to pharmaceutical-based antidepressant 
therapy may be explained by selective FDA clinical efficacy report 
publications, which artificially inflate antidepressant drug efficacy 
and lead to a false sense of security in physicians prescribing them. 
IntroductIon
Depression is among the top predictors of mortality and sub-
standard  daily  functioning  in  North  America,  second  only  to 
cardiovascular disorders (Wells et al., 1989). Due to conventional 
symptom-based classification schemes and an incomplete under-
standing of the disorder, the term “depression” is used to describe 
a broad set of disparate pathologies sharing a common set of 
symptoms – pathologies that manifest as abnormal control and 
expression of mood and emotion (Davidson et al., 2002). Depressed 
individuals may experience a dispirited mood, a lowered sense of 
enthusiasm or enjoyment with routine tasks, a disrupted sleep 
schedule, altered behavior, appetite, or weight, a change in the 
speed of muscle movements, a decreased energy level, an inability 
to focus, thoughts of worthlessness or guilt, and thoughts of death 
or suicide over an extended period of time (First and Ross, 2000; 
Kroenke et al., 2001). Current treatment measures do not effec-
tively control symptoms in most depressed patients, especially the 
estimated 4 million Americans with a severe treatment-resistant 
subtype known as refractory major depressive disorder (refractory 
MDD) (Kessler et al., 2005; Cyberonics, 2007).
Refractory MDD is characterized by recurrent, long-lasting cycles 
of severe, often suicidal depressive episodes that do not remit using 
multiple types of antidepressant therapies. A depressive episode 
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In fact, a recent meta-analysis of 74 published and   unpublished 
  antidepressant   efficacy trials, involving 12 antidepressant drugs and 
12,564 participants, showed that only 51% of the trials whose data 
was submitted to the FDA ended with positive results (While 94% 
of the published efficacy reports show positive results) (Turner 
et al., 2008). A separate meta-analysis of 47 published and unpub-
lished FDA clinical trial datasets from selective-serotonin reuptake 
inhibitor (SSRI) efficacy trials showed that six of the seven most-
  prescribed  SSRI  antidepressant  drugs  available  within  the  last 
25 years only show clinically significant benefits over placebo for 
“the upper end of the very severely depressed category” (Kirsch 
et al., 2008). The latter study suggests that SSRIs, which are most 
often the first class of prescribed drugs for depressive disorders, pose 
greater risks to patient health than benefits for symptom relief in 
the majority of patients (Kirsch et al., 2008; Turner et al., 2008).
Stimulation-based  technologies,  designed  to  electrically  or 
chemically  modulate  abnormal  neural  activity,  are  emerging 
as potential therapeutic options for refractory MDD patients. 
However, the expected treatment efficacies of these technolo-
gies, as with all antidepressant treatments, are burdened by an 
incomplete understanding of the pathophysiology of depressive 
disorders and a lack of reproducible and quantifiable biological 
markers  (i.e.,  biomarkers)  of  depressed  states  (antidepressant 
treatment response is still subjectively evaluated using patient-
reported  symptom  relief,  effectively  ignoring  the  prospect  of 
using objectively-quantified, depression-linked biomarker levels 
to quantify antidepressant responses and to optimize treatment). 
With modern research tools, additional structural, functional, and 
genetic abnormalities associated with depression are discovered 
each year. Concomitantly, several quantifiable genetic, biochemi-
cal, and bioelectric diagnostic markers of depression are emerging. 
Similar discoveries in the epilepsy research field sparked interests 
in closed-loop neuroprostheses, where biological indicators of 
an impending seizure are used to determine the time at which 
an electrical or chemical stimulus must be applied to stop a sei-
zure (Dumitriu et al., 2008). This process, known as responsive 
neurostimulation, is unique to closed-loop devices. It is intended 
to replace continuous or periodic open-loop stimulation designs 
so that tailored therapy, based on quantifiable symptom-linked 
biomarker abnormalities, is provided in a dose-dependent man-
ner only when it is necessary (Sun et al., 2008; Goodman and 
Insel, 2009).With time, closed-loop neurostimulation devices for 
refractory MDD are expected to bridge the knowledge gap that 
currently exists between subjective antidepressant response evalu-
ations and quantifiable antidepressant responses due to controlled 
therapeutic stimuli.
Closed-loop treatments are now rapidly emerging for a vari-
ety of treatment-resistant disorders with encouraging successes 
(Sun et al., 2008; Wong et al., 2008; Behrend et al., 2009). Despite 
the recent advancements in depression research, no closed-loop 
prosthesis exists for treating refractory MDD. Failing pharma-
ceutical  antidepressants,  newly  discovered  therapeutic  targets 
common to most subtypes of the disorder, emerging biological 
markers of depression, and advancements in other research fields 
are paving the road for closed-loop neuroprosthesis development. 
Using real-time input from simple micro-fabricated biosensors to 
determine when, where, and what type of stimulus to apply, such 
  near-  autonomous devices promise to provide highly efficacious 
therapy to   dysfunctional brain structures in a dose-dependent 
manner only when it is needed. However, several hurdles must be 
overcome before any such device can be used in clinical practice.
The purpose of this review is to critically assess the current lit-
erature on refractory MDD diagnostic methodologies, theories of 
depressive disorder pathogenesis, and treatment methodologies in 
order to define the need for more efficacious closed-loop treatment 
alternatives and propose means of attaining them. This review first 
addresses current diagnostic and treatment schemes for depres-
sive disorders, theories of MDD pathogenesis/pathophysiology, 
and alternative stimulation-based antidepressant therapies. Next, 
the review presents promising stimulation targets and candidate 
quantifiable biological markers of depression in context with the 
current theories of MDD pathophysiology. To conclude, a modu-
lar closed-loop neurostimulation device design framework is pro-
posed, utilizing real-time biomarker level measurements as control 
points for initiating and terminating an autonomously optimized 
corrective electrical stimulus.
current Mdd dIagnostIc and pharMaceutIcal 
treatMent protocols
Depression  is  currently  diagnosed  through  an  evaluation  of  a 
patient’s  reported  symptoms,  clinical  history,  and  full  physi-
cal  examination.  A  patient  is  often  initially  assessed  using  a 
  depression-specific standardized evaluation such as 9 item Patient 
Health Questionnaire (PHQ-9), Hamilton Depression Rating Scale 
(HAM-D or HDRS), or Montgomery–Asberg Depression Rating 
Scale (MADRS) (Kearns et al., 1982; Kroenke et al., 2001). Each 
survey is used to estimate the severity of the symptoms used to 
diagnose depression in accordance with DSM-IV criteria (refer to 
the first paragraph of the introduction for a full list of common 
symptoms). The patient’s clinical history and physical examination 
are then used to rule out other obvious and treatable explanations 
for the symptoms (DepressionGuidelinePanel, 1994).
Diagnosing refractory MDD is a lengthy process that often is 
not in the best interest of the patient’s health due to potentially 
life-threatening antidepressant side effects (e.g., violent behavior, 
cardiovascular problems, and/or recurrent thoughts of death/
suicide) (Peretti et al., 2000; Mann, 2005). The most common first 
line of treatment for an MDD patient is psychotherapy and/or a 
low-dose SSRI antidepressant therapy. In psychotherapy sessions, 
a patient is taught to change thinking and behavior patterns in 
an effort to modulate limbic-cortical pathways in regions of the 
prefrontal cortex, hippocampus, and cingulate that are associated 
with normal emotions and behavior (Goldapple et al., 2004). 
After a recommended 6–12 weeks on a particular antidepressant 
(Quitkin et al., 1986; Mann, 2005), effectiveness may be assessed 
using the HAM-D or MADRS questionnaire (Despite the rec-
ommended evaluation timeframe, efficacy is typically assessed 
after 4–6 weeks of treatment). If the patient shows some benefit 
with zero or non-problematic symptoms, a higher dose of the 
same medication or a second antidepressant is prescribed. If a 
patient receives no significant benefit from at least two properly 
prescribed antidepressants (i.e., correct dose and sufficient evalu-
ation timeframe), he or she is diagnosed with refractory MDD 
(Dumitriu et al., 2008). The level of treatment resistance is then Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  3
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and assumed functions of various brain regions, researchers found 
that depressive disorders are often associated with neurotrans-
mitter imbalances (most notably serotonin, norepinephrine, and 
dopamine, Mann, 2005) and reduced blood flow, neurogenesis, and 
relative amounts of neurotrophic factors in regions of the limbic 
system (most notably the hippocampus) and prefrontal cortex 
(Belmaker and Agam, 2008). More recent findings implicate stress 
and a compromised immune system as possible causal factors in 
depressive disorder pathogenesis (O’Brien et al., 2007; Dantzer 
et al., 2008). To date, no clear links between these observations 
have been established.
Through modern functional neuroimaging studies and post-
mortem investigations, researchers discovered numerous structural 
and functional abnormalities associated with depressive disorders 
(Mayberg et al., 1999, 2000; Milak et al., 2005; Goodman and Insel, 
2009). An important clue that led to these findings is the com-
monality of cognitive impairments, or the “diminished ability to 
think or concentrate,” seen in patients with depressive disorders 
(Pittenger and Duman, 2008). Since the hippocampi are critical for 
memory and learning, and since they have extensive projections 
to many brain areas associated with these functions, researchers 
were able to implicate a dysfunctional prefrontal cortex, hypotha-
lamus, thalamus, amygdala, nucleus accumbens, and subgenual 
cingulate in depressive disorders (Nestler et al., 2002; Pittenger 
and Duman, 2008).
In light of recent advancements, most investigators agree that 
depression  is  a  multifaceted  disorder  in  which  heterogeneous 
genetic and environmental factors predispose certain individuals 
to depressed states. These depressed states are brought about by 
an underlying “system-level disorder affecting discrete, but func-
tionally integrated (biological) pathways” (Mayberg, 1997). In the 
remainder of Section “Overview of MDD Pathogenesis”, several of 
the major theories of depressive disorder pathogenesis are reviewed 
in order to establish candidate stimulation targets and biomarkers 
that can be incorporated into the design of closed-loop neuropros-
theses for differing manifestations of refractory MDD.
MonoaMIne-defIcIency hypothesIs
The dominant hypothesis from 1967 until well into the 1990s was 
the monoamine-deficiency hypothesis of depression, a hypoth-
esis  implicating  dysfunctional  serotonin,  norepinephrine,  and 
dopamine systems in depressive disorder pathogenesis (Coppen, 
1967).  Several  observations  led  to  and  helped  strengthen  this 
hypothesis: (1) experimentally depleting tryptophan in a previ-
ously depressed subject treated with a SSRI will cause a relapse into 
a depressed state, while depleting tryptophan in a non-depressed 
subject will not (tryptophan is required for normal serotonin pro-
duction); similarly, experimentally depleting tyrosine hydroxylase 
in a previously depressed subject treated with a norepinephrine-
reuptake inhibitor (NERI) will cause a relapse into a depressed state, 
while depleting tyrosine hydroxylase in a non-depressed subject will 
not (tyrosine hydroxylase is required for normal norepinephrine 
production) (Mann, 2005; Ruhe et al., 2007; Belmaker and Agam, 
2008);  (2)  certain  effective  antidepressants  block  monoamine 
neurotransmitter reuptake in the presynaptic terminals or inhibit 
monoamine oxidase (an enzyme required for breaking down sero-
tonin and norepinephrine), increasing the availability of serotonin 
estimated using one of several non-standardized algorithms, most 
notably the 5 stage model put forth by Thase and Rush (1997) 
(Dumitriu et al., 2008).
The majority of adults visit primary care physicians in lieu of 
mental health specialists when they believe they are depressed, lead-
ing to inaccurate diagnoses in more than 50% of patients (Cepoiu 
et al., 2008). Misdiagnoses likely occur because no quantifiable 
measures of depression are currently used in clinical medicine, 
forcing  physicians  to  interpret  somewhat  unreliable  subjective 
assessments obtained through standardized evaluations such as the 
PHQ-9. Therefore, the treatment-resistant subset of patients may 
be smaller than what is reported in literature, because they were 
inaccurately diagnosed and suffer from another underlying disorder 
(e.g., heart disease, rheumatoid arthritis, or cancer). Consequently, 
failed antidepressant treatments may not indicate that a patient is 
treatment-resistant, but rather that his or her depressive symptoms 
are secondary to another undetected or developing disease. Objective 
diagnostic tests based on quantifiable depressive   disorder-specific 
biomarkers are needed to improve diagnostic accuracy and the clas-
sifications of differing manifestations of the disorder.
In summary, a major contributor to failing depressive disor-
der treatments stems from the lack of objective diagnostic crite-
ria, which impedes more accurate distinctions among depressed 
patients who share the same common symptom profile, but develop 
depressive disorders through differing circumstances (Lacasse and 
Leo, 2005). With this in mind, antidepressant drug therapy is akin to 
moderately effective broad-spectrum antibiotic therapy for bacte-
rial infections: the same drug is given to patients who have different 
underlying disorders in hopes of restoring normal health without 
determining the specific underlying causes of the illnesses or moni-
toring the effects on the assumed drug targets. Such a strategy is 
currently acceptable with broad-spectrum antibiotics due to their 
general safety, well-defined targets, known mechanisms of action, 
and proven therapeutic efficacy. Since antidepressant therapies do 
not have well-defined targets, proven mechanisms of action, and 
consistent reports of clinical efficacy, it is no surprise that vary-
ing levels of treatment resistance are consistently reported (Thase 
and Rush, 1997; Fava, 2003; Mann, 2005; Belmaker and Agam, 
2008; Kirsch et al., 2008). More individually tailored antidepres-
sant therapies are needed if enhanced therapeutic efficacies are 
desired in the refractory population. Closed-loop neuroprosthetic 
devices show great promise for providing such tailored therapies in 
the foreseeable future. Section “Overview of MDD Pathogenesis” 
first presents well-known aspects of MDD and concludes with the 
debated theories of its development and manifestation. The infor-
mation is intended to highlight the heterogeneous nature of MDD, 
which drives the need for a heterogeneous set of treatments.
overvIew of Mdd pathogenesIs
depressIon as a MultI-systeM dIsorder
The pathophysiological aspects of depressive disorders are not 
well understood. From prospective heritability studies, it is clear 
that genetics and environmental factors (i.e., nature and nurture) 
play synergistic roles in individual susceptibility to developing the 
disorder (Heils et al., 1996; Sullivan et al., 2000; Caspi et al., 2003; 
Kendler et al., 2005; Bradley et al., 2008). Using predominantly qual-
itative observations of depressive disorders, treatment responses, Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  4
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  depression is that it cannot clearly separate many   nosologically-distinct 
neurological  disorders  from  depressive  disorders  (and  healthy 
patients from depressed patients) due to overlapping mean cortisol 
and CRH levels in most healthy and depressed patients, the large 
circadian-rhythm-associated plasma cortisol level fluctuations nor-
mally seen within the general population, and the association of 
the cortisol system with other distinct disorders (Burke et al., 2005; 
Belmaker and Agam, 2008). A second major problem with the HPA-
axis theory is that the negative effects of long-term exposure to high 
cortisol levels partially remit when synaptic monoamine neurotrans-
mitter availability is increased (e.g., through antidepressant action, 
but demonstrated with selective depletion of select monoamine 
neurotransmitters) (Carroll et al., 2007). In light of these observa-
tions, Belmaker and Agam (2008) suggest that antidepressants do not 
directly improve mood; rather, they reduce “secondary stress caused 
by a painfully dispirited mood,” thereby indirectly elevating mood by 
reducing an exacerbating cause (i.e., prolonged stress). They propose 
that such a mechanism of antidepressant action may help explain why 
antidepressants successfully treat such a variety of non-depressive 
neurological disorders (e.g., anxiety disorders and post-traumatic 
stress disorders) (Belmaker and Agam, 2008).
neurotrophIc theory of depressIon
A third hypothesis of depressive disorder pathogenesis developed 
mostly throughout the last decade, building upon the monoamine-
deficiency hypothesis and the HPA-axis theory of depression. The 
neurotrophic theory of depression postulates that (1) reduced 
brain-derived neurotrophic factor (BDNF) and vascular endothelial 
growth factor (VEGF) in the hippocampus and associated limbic 
structures, originating from chronic exposure to stress hormones 
in susceptible individuals, causes or worsens depressive disorders, 
and that (2) effective antidepressants contribute to neurotrophic 
factor upregulation in the dysfunctional limbic structures by restor-
ing normal HPA-axis function (i.e., Antidepressants work to lower 
stress levels and increase BDNF availability, thereby allowing natu-
ral repair mechanisms to correct functional deficits and ultimately 
reduce symptoms) (Duman and Monteggia, 2006; Pittenger and 
Duman, 2008).
Key observations leading to and strengthening this theory are: 
(1) neurotrophic factors, especially BDNF and VEGF, are under-
expressed in limbic structures implicated in depression (especially 
the hippocampus) and may contribute to their observed atrophy 
and increased sensitivity to death (Sapolsky, 2000; Duman and 
Monteggia, 2006); (2) HPA-axis dysfunction exacerbates this phe-
nomenon, while effective antidepressant treatments counteract it 
by enhancing hippocampal BDNF mRNA expression through the 
cAMP-CREB cascade (Duman et al., 1997, 2000); and (3) ECT 
and MAOI antidepressants, considered to be the most effective at 
relieving depressive symptoms, were shown to most significantly 
increase BDNF and trkB (the BDNF receptor) mRNA expression 
in the hippocampus (Nibuya et al., 1995).
adult hIppocaMpal neurogenesIs and cellular plastIcIty 
theory of depressIon
A fourth hypothesis of depressive disorder pathogenesis, known 
as the adult hippocampal neurogenesis and cellular plasticity the-
ory of depression, closely resembles the neurotrophic theory of 
and norepinephrine for postsynaptic neurotransmission (Mann, 
2005; Belmaker and Agam, 2008); and (3) monoamine neuro-
transmitters are used in most parts of the brain, therefore allow-
ing the possibility of explaining the broad spectrum of underlying 
pathologies classified as depression (Mann, 2005; Belmaker and 
Agam, 2008).
Several recent investigations and literature analyses have discred-
ited this theory by questioning its origin, re-evaluating published and 
unpublished clinical efficacy data, and elucidating other actions of 
effective antidepressants (Lacasse and Leo, 2005; Kirsch et al., 2008; 
Turner et al., 2008). The largest flaw in the monoamine-deficiency 
hypothesis is in its origin. It originated in 1967 from observations 
of the mechanisms of action of clinically effective antidepressants, 
which were known to block serotonin and norepinephrine reuptake 
at the presynaptic terminals. On average, however, no significant 
differences in monoamine neurotransmitter levels and dynam-
ics are seen in depressed versus control patients (Belmaker and 
Agam, 2008). Additionally, a meta-analysis conducted by Kirsch and 
others (on SSRI therapeutic efficacies) demonstrated that 80% of 
the antidepressant responses seen in the experimental groups are 
also seen in the control/placebo groups with no significant effect 
imparted by SSRI dose (Kirsch, 2002; Lacasse and Leo, 2005; Kirsch 
et al., 2008). As a result, many academics believe that dysfunctional 
monoamine neurotransmitter systems are likely just downstream 
effects of another underlying disorder leading to the symptoms of 
depression (Belmaker and Agam, 2008).
hypothalaMIc–pItuItary–adrenal axIs theory of depressIon
A second hypothesis of depression, known as the hypothalam-
ic–pituitary–adrenal  (HPA)-axis  theory  of  depression,  arose 
in 1996 after researchers published evidence linking abnormal 
  corticotropin-releasing hormone (CRH), corticotropin (ACTH), 
and cortisol dynamics/regulation to depressive disorders (Holsboer 
and Barden, 1996). The HPA-axis theory postulates that corticos-
teroid-receptor signaling is disrupted by some external mechanism, 
increasing CRH synthesis and release in brain structures impli-
cated in depression and culminating in its pathogenesis (Holsboer, 
2000). Specifically, prolonged exposure to elevated levels of stress 
hormones increases atrophy and the susceptibility of neurons and 
glial cells to damage and death, particularly in the hippocampus 
(Sapolsky, 2000; Duman and Monteggia, 2006). Observations lead-
ing to and strengthening this theory are: (1) elevated CRH and 
cortisol levels were observed in the cerebrospinal fluid (Nemeroff 
et al., 1984; Merali et al., 2004) and plasma (Burke et al., 2005) 
of depressed patients, respectively; (2) higher levels of cortisol 
and ACTH secretions were detected from urinalysis in depressed 
patients (Rubin et al., 1987); (3) higher levels of CRH and CRH 
mRNA were found in depression-associated limbic structures of 
depressed patients who committed suicide (Merali et al., 2004); (4) 
researchers showed that 50% of severely depressed patients lacked 
a normal “cortisol-suppression response” through dexamethasone 
suppression tests (Carroll et al., 2007); and (5) HPA-axis function 
returns to more normal states with successful antidepressant thera-
pies (Carroll et al., 2007; Belmaker and Agam, 2008).
As with the monoamine-deficiency hypothesis, the HPA-axis 
theory lacks proof and consistently reproducible results in support 
of the hypothesis. One major problem with the HPA-axis theory of Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  5
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depressive disorders and can produce sufficient symptoms for a 
diagnosis of a major depressive episode (Smith, 1991; Yirmiya et al., 
2000); (4) comorbid diseases that are often seen in patients with 
severe depressive disorders, such as rheumatoid arthritis or heart 
disease, involve significant macrophage activation (possibly as a 
result of chronic inflammatory effects, Dantzer et al., 2008) (Smith, 
1991); and (5) Yirmiya et al. (2000) showed that antidepressants 
can alleviate the symptoms of sickness behavior.
O’Brien et al. (2007) showed that SSRI-resistant MDD patients 
have significantly higher IL-6 and TNF-α levels in blood plasma 
than healthy controls and SSRI-resistant MDD patients who suc-
cessfully responded to another class of antidepressants (O’Brien 
et  al.,  2007).  They  conclude  that  pro-inflammatory  cytokine 
expression (specifically IL-6 and TNF-α) is higher in refractory 
MDD patients versus normal patients and that a failure of pro-
inflammatory cytokine suppression is linked to SSRI resistance in 
refractory MDD patients. Biomarkers of SSRI-resistant depressive 
disorders may serve as a means of distinction among refractory 
MDD patients whose depressive disorders arise through different 
underlying mechanisms. However, the utility will largely depend 
on whether similar biomarker-based distinctions are observed in 
refractory MDD patients with differing drug resistance profiles.
Each theory discussed so far has common features that may 
be causal in depressive disorders, but none are as far-reaching as 
the macrophage theory of depression. The macrophage theory of 
depression is useful for finding quantifiable depressive disorder 
diagnostic biomarkers, since its general framework can account 
for  many  of  the  assumed  underlying  causes  and/or  effects  of 
depressive disorders (e.g., The macrophage theory accounts for 
the large percentage of chronically ill patients that are diagnosed 
with comorbid depression) and for certain cases of treatment resist-
ance. However, it does not explain whether a depressive disorder 
or chronic illness must be present at the same time or whether a 
depressive disorder leads to chronic illness (or vice versa). Section 
“Alternative Therapies for Refractory Major Depressive Disorders” 
discusses non-pharmaceutical, electromagnetic-stimulation-based 
antidepressant therapies that are most often used when pharma-
ceutical antidepressant therapy, psychotherapy, and/or ECT fail in 
a given patient.
alternatIve therapIes for refractory Major 
depressIve dIsorders
If drug-based antidepressant therapies are ineffective in a given 
patient, few alternative options remain. In severe cases, ECT is most 
commonly used over several weeks to help control depressive symp-
toms. This traditional treatment paradigm for treatment-resistant 
patients involves non-specific, but noninvasive stimulation of broad 
regions of the cortex. The patients must be lightly anesthetized and/
or sedated and often experience significant adverse side effects (e.g., 
retrograde amnesia that often does not fully improve over time) 
(Marangell et al., 2007; Dumitriu et al., 2008). However, despite its 
inherent limitations, ECT has provided more antidepressant benefits 
to refractory MDD patients than any other FDA-approved treatment 
option. ECT will not be further addressed in this review, because 
it is not a suitable technology for implantable, closed-loop neuro-
prosthetic devices. The remainder of Section “Alternative Therapies 
for Refractory Major Depressive Disorders” discusses current and 
depression, but attempts to address the roles of   neurotransmitters 
in depressive disorders. The hypothesis attributes neuronal vol-
ume reductions and morphological changes observed in the hip-
pocampi of depressed subjects to a failure of neurogenesis and 
general cellular plasticity in the granule cell layer of the dentate 
gyrus (Jacobs et al., 2000; Kempermann and Kronenberg, 2003). 
Other than observed structural deficits in key limbic regions, the 
hypothesis was inspired largely by discovering that elevated sero-
tonin levels, not just elevated neurotrophic factor levels, increases 
hippocampal neurogenesis (i.e., Successful therapies relieve depres-
sive symptoms through more than one pathway) (Jacobs et al., 2000; 
Kempermann and Kronenberg, 2003). Due to the large number of 
projections from the hippocampus to brain structures implicated 
in depression, it is proposed that cycles of decreased or increased 
hippocampal neurogenesis (Jacobs et al., 2000) and cellular plastic-
ity (Kempermann and Kronenberg, 2003) causes episodes of and 
remission from depressive episodes and may explain the hetero-
geneous nature of the disorder.
A major drawback to testing this theory is the difficult nature 
of accurately quantifying cellular plasticity, especially using non- 
or minimally-invasive techniques (Kempermann and Kronenberg, 
2003). The neurotrophic theory involves mostly quantifiable mark-
ers of depression, using the effects of the HPA-axis and neuro-
trophins to explain the pathogenesis of depressive disorders. While 
the adult hippocampal neurogenesis and cellular plasticity theory of 
depression considers the roles of stress and BDNF in neurogenesis, 
they are not strict requirements. The non-specific nature of the 
hypothesis provides a framework for more specific hypotheses, 
making it useful even if it does not directly lead to an understand-
ing of depressive disorder pathogenesis.
Macrophage theory of depressIon
A fifth, highly-promising hypothesis of depressive disorder patho-
genesis considers the role of the immune system in the pathogenesis 
of depression, specifically drawing upon the parallels between the 
symptoms and behaviors linked to depression and “sickness behav-
ior” (a term used to describe physically ill patients with various 
infections and/or diseases that chronically activate the immune 
system and cause symptoms indicative of depression) (Dantzer 
et al., 2008). Several observations led to the macrophage theory of 
depression, which states that depressive disorders arise from the 
effects of abnormally high levels of cytokine production: (1) pro-
inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) 
and interleukin-1β (IL-1β), are soluble inflammatory factors pro-
duced by activated immune cells at a site of infection to promote 
local  inflammation  and  often  broader,  systemic  inflammatory 
effects. These cytokine-mediated systemic effects can adversely 
affect brain function, where the cytokine-mediated inflammation 
is linked to the behaviors typically observed with depressive disor-
ders and severe illnesses (e.g., smaller appetite, impaired memory, 
irritability, depressed mood, impaired attention, etc.) (Dantzer 
et al., 2008); (2) pro-inflammatory cytokine receptors have been 
identified in most areas of the brain, although the quantity of recep-
tors per cell is usually small and varies depending on the region of 
the brain (Konsman et al., 2004; Dantzer et al., 2008); (3) acutely 
introducing pro-inflammatory cytokines in a normal subject can 
chronically disturb hormone dynamics to what is often seen in Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  6
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tivity over ECT, noninvasive nature, and generally tolerable side 
effects (Figiel et al., 1998; Klein et al., 1999; Janicak et al., 2008). As 
a result, TMS is now used as an FDA-approved treatment option 
for refractory MDD.
Transcranial magnetic stimulation is typically administered by 
pulsing a current through a circular or figure-8 coil positioned over 
the cortical regions of interest. The resulting oriented magnetic 
field pulses generate an electric field within the superficial layers 
of cortex (with a maximum depth of 1 cm, Dumitriu et al., 2008), 
depolarizing neurons when a sufficient electric field is generated 
(Fitzgerald et al., 2002).Device size limitations preclude the use 
of this technology in a fully implantable closed-loop neuropros-
thesis. Current TMS devices are large and typically only accessible 
through outpatient procedures (such as NeuroStar® TMS Therapy, 
Neuronetics, 2009). TMS device size, which is proportional to the 
size of the stimulated cortical area, is limited by a tradeoff between 
coil size and the magnitude of current required to generate the same 
magnetic field in a smaller device (Cohen and Cuffin, 1991). As a 
result, TMS is not suitable for use in a fully implantable neuropros-
thesis unless fundamental design changes are made to considerably 
decrease device size without sacrificing performance.
There are many subtypes of TMS, classified according to stimu-
lation parameters and mode of application. In this review, two tra-
ditional subtypes are considered: rapid-rate/repetitive transcranial 
magnetic stimulation (rTMS – includes any stimulation paradigm 
using frequencies >1 Hz) and low-frequency/slow transcranial 
magnetic stimulation (sTMS – includes any stimulation paradigm 
using frequencies ≤1 Hz). The TMS subtypes produce differing 
cortical activation properties – depending largely on stimulation 
parameters, coil shapes and sizes, stimulation sites, and stimulation 
orientations – and are associated with studies that report conflicting 
therapeutic efficacies. However, it is believed that rTMS produces 
more antidepressive effects, as one study of cerebral blood flow 
showed significant increases in blood supply to prefrontal cortical 
and limbic regions following rTMS and marked decreases following 
sTMS (Speer et al., 2000).
deep braIn stIMulatIon
Deep brain stimulation (DBS) was first used for treating depres-
sion in 1954 (Poole, 1954; Hardesty and Sackeim, 2007). However, 
DBS gained considerable research interest and momentum in 1987, 
when Benabid et al. (1987) successfully relieved Parkinsonian trem-
ors in a patient through high-frequency stimulation of one thalamic 
nucleus ventralis intermedius and removal of the other. Benabid 
et al.’s paper showed that high-frequency electrical stimulation of a 
dysfunctional brain structure was as effective as surgically remov-
ing the same part of the brain, thereby promoting DBS therapy as 
a less-invasive and less-extreme alternative to resection surgeries 
(Benabid et al., 1987; Hardesty and Sackeim, 2007).
The power of DBS in treating refractory psychiatric disorders 
has become increasingly apparent throughout the last few decades, 
largely through unexpected side effects observed in non-depressed 
DBS patients. For example: in an older woman without any known 
psychiatric disorders (implanted with a deep brain stimulator for 
Parkinson’s disease), high-frequency DBS therapy applied to the 
left substantia nigra caused temporary suicidal depression that 
reversed  once  stimulation  ceased  (The  electrical  stimulus  was 
upcoming treatment alternatives, addressing the limitations of each 
therapy as they relate to stimulation/therapeutic targets, therapeutic 
efficacy, and utility in a closed-loop therapeutic device.
vagus nerve stIMulatIon
The prospect of using vagus nerve stimulation (VNS) as an alterna-
tive therapy for refractory MDD originated from unexpected patient-
reported mood improvements observed in the NeuroCybernetic 
Prosthesis System trials in the 1990s (Ben-Menachem et al., 1994) 
and the off-label uses of specific seizure medications for stabiliz-
ing mood disorders (Ballenger and Post, 1980; Post et al., 1986; 
George et al., 2000). Several treatment-resistant epileptic patients 
implanted with the VNS device reported significant mood eleva-
tions that researchers could not solely attribute to seizure frequency 
reduction. Additional positron-emission tomography (PET) stud-
ies showed that VNS reduced cingulate activity, the same effect seen 
from many successful antidepressant therapies (George et al., 2000), 
and altered blood flow and metabolism in limbic structures (Henry 
et al., 1998). Other investigations showed that neurotransmitter 
levels are altered as a result of VNS (Ben-Menachem et al., 1995; 
Krahl et al., 1998). Due to these observations, the first VNS stimula-
tion device for treating unipolar refractory MDD was implanted 
by Rush and colleagues (1998) (George et al., 2000; Rush et al., 
2000). FDA approval followed in July, 2005 (George et al., 2000; 
Nemeroff et al., 2006).
The VNS device implantation procedure is rather straightfor-
ward. Under general anesthesia, the VNS device housing is surgically 
implanted in the left chest wall. A projecting stimulation lead with 
an attached helical electrode is then wrapped around the left cervical 
vagus nerve and secured to surrounding tissue. The device is exter-
nally activated and programmed using a wand-like device placed 
over the left chest wall. Stimulation is intermittent and commonly 
programmed for 30 s of monophasic, constant-current stimula-
tion every 5 min. However, individual parameters are adjusted on 
a patient-to-patient basis in order to achieve maximal therapeutic 
efficacy with minimal side effects (Marangell et al., 2007).
The efficacy of the current VNS device for treating depression 
is disputed. In the 2000 paper summarizing the study’s outcome, 
Rush et al. report antidepressant responses in 40% of the 30 patients 
who were enrolled. However, statistically significant reductions in 
depression rating scale scores were not observed for the experi-
mental group as a whole (Rush et al., 2000). In 2004, Carpenter 
et al. showed that monoamine neurotransmitter metabolites, nore-
pinephrine, and GABA levels did not significantly change over a 
24-week study, noting that “the results do not suggest a putative 
antidepressant mechanism of action for VNS” (Carpenter et al., 
2004). Additional controlled studies with larger sample sizes are 
needed to make any definitive conclusions.
transcranIal MagnetIc stIMulatIon
Transcranial  magnetic  stimulation  (TMS)  was  introduced  by 
Barker et al. (1985) (Klein et al., 1999). By noninvasively activat-
ing target cortical regions, TMS allows investigators to selectively 
study brain function in a simplified and relatively safe manner 
(Figiel et al., 1998; Klein et al., 1999). In the last few decades it has 
received considerable interest as a therapeutic tool in a variety of 
neurological disorders, stemming from its favorable spatial selec-Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  7
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DBS is heavily researched due to its promise of rapidly modulating 
dysfunctional network   activity to desired states in a dose-dependent 
manner only when it is needed. Harnessing the full power of this 
therapy, however, will require a closed-loop system that autono-
mously adjusts output stimulus parameters in order to maintain 
disease- or symptom-linked biomarkers within normal levels.
stIMulatIon targets for refractory Mdd
Few neural stimulation targets have been evaluated for treatment 
efficacy in the refractory MDD population (Table 1). In general, 
proposed stimulation targets are linked to limbic structures and 
come directly from hypotheses of neural dysfunction in   depression, 
imaging studies, unexpected mood improvements observed in stim-
ulation studies treating other disorders, and areas accessible with a 
given stimulation technology. The VNS system specifically targets 
the left cervical vagus nerve (Ben-Menachem et al., 1994; George 
inadvertently applied 2 mm below the optimal site of   stimulation 
for Parkinson’s symptom relief) (Bejjani et al., 1999; Hardesty 
and Sackeim, 2007). In a separate case study of DBS for treating 
comorbid obsessive-compulsive disorder with Parkinson’s disease, 
Fontaine et al. (2004) demonstrated that the choice of stimulation 
parameters (applied in the sub-thalamic nucleus) largely deter-
mined the level of   obsessive-compulsive disorder symptom relief. 
The temporary induction of severe depressive symptoms in the 
older woman indirectly highlights the power of DBS as a means 
of rapidly and reversibly modulating neural function. However, it 
also cautions that the therapeutic efficacy of any treatment heavily 
depends on the specificity of its delivery, as a small targeting error 
can induce potentially   dangerous nonlinear side effects. The lat-
ter case study shows that DBS therapeutic efficacy is largely dose-
dependent in addition to site-dependent (Fontaine et al., 2004; 
Hardesty and Sackeim, 2007). Hence, despite its invasive nature, 
Table 1 | Stimulation targets for treating refractory MDD.
Target structure  Motivation  Stimulation type  N  Responders  Proposed mechanism of action
Subcallosal cingulate  Overactive SCG glucose  DBS  6  66.7%a (Mayberg  Modulates neural 
gyrus (SCG) (Mayberg et al.,   metabolism seen in MDDs that  Continuous    et al., 2005)  pathways associated with 
2000, 2005; Lozano et al., 2008)  is reduced with successful  Constant V  20  60%a  emotion (Lozano et al., 2008)
  antidepressant therapies (Mayberg  Monophasic    (Lozano et al., 2008)   
  et al., 1999; Lozano et al., 2008)   
Ventral capsule/ventral  Antidepressant effects seen from  DBS  15  40%a (Malone  Modulates neural pathways
striatum (VC/VS)   VC/VS stimulation for severe OCD;   Continuous    et al., 2009)  associated with OCD and
(Malone et al., 2009)   (Nuttin et al., 1999; Greenberg  Constant V      depression (Malone et al., 2009)
  et al., 2006)  Biphasic     
Left cervical vagus nerve  Antidepressant effects seen  VNS  30  55%a,b (Marangell  Modulates neural pathways
(George et al., 2000; Rush et al.,   from VNS for epilepsy  Intermittentb   et al., 2002)  associated with mood
2000; Goodman and Insel, 2009)  (Rush et al., 2000)  Constant I      regulation via the nucleus tractus
    Monophasic      solitarius (Nemeroff et al., 2006)
Right dorsolateral prefrontal  PFC functions are disrupted in  sTMS  35  49%c (Klein  Modulates right PFC activity
cortex (DLPFC) (Klein et al., 1999)  depression and sTMS of right  2 weeks    et al., 1999)  associated with mood
  DLPFC has antidepressive effects  10 Sessions      regulation (Klein et al., 1999) 
 ( Fitzgerald et al., 2006)
Left dorsolateral prefrontal cortex  PFC functions are disrupted in  rTMS  35  30.6%c (Avery  Modulates left PFC activity
(DLPFC) (Speer et al., 2000;   depression and rTMS of left  4 weeks  25  et al., 2006) 44%d  and increases cerebral blood
Avery et al., 2006)  DLPFC has antidepressive  15 Sessions    (Fitzgerald et al., 2006)  supply (Speer et al., 2000) 
  effects (Fitzgerald et al., 2006)
Globus pallidus internus (GPI)  Some antidepressant effects seen  DBS  1  100% (case study)   Modulates mesolimbic
(Halbig et al., 2005;   from GPI stimulation for dystonia  Continuous   ( Kosel et al., 2007)  dopaminergic pathways
Kosel et al., 2007)  (Halbig et al., 2005; Kosel et al., 2007)  Constant V      (Kosel et al., 2007)
    Monophasic     
Inferior thalamic peduncle (ITP)   ITP stimulation may modulate  DBS  1  100% (case study)   Modulates orbitofrontal
(Jimenez et al., 2005;   dysfunctional thalamo-orbitofrontal  Continuous   ( Jimenez et al., 2005)  cortex hyperactivity
Velasco et al., 2005)  system activity (Velasco et al., 2005)  Constant V      (Velasco et al., 2005)
    Biphasic     
OCD, obsessive-compulsive disorder; s/rTMS, slow/rapid transcranial magnetic stimulation.
aResponse is defined as a ≥ 50% decrease in the 17-, 24-, or 28-question Hamilton Depression Rating Scale (HDRS) score 6 months after implantation (relative to 
scores from the same HDRS survey before implantation) (Marangell et al., 2002; Mayberg et al., 2005; Malone et al., 2009).
bAntidepressant “treatment as usual” and medication changes were allowed during the VNS study period (Nemeroff et al., 2006).
cReported percentage of responders represents responses after 10 treatment sessions over 2 weeks (Klein et al., 1999) or 15 treatment sessions over 4 weeks 
(Avery et al., 2006), respectively (using the same response criteria as outlined in (a) above).
dThis study used sTMS of the right DLPFC followed by rTMS of the left DLPFC for a 6-week period (Fitzgerald et al., 2006).Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  8
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Stimulation programming procedures are often uncomfortable 
for the patient, as severe side effects are often induced due to unin-
tended neural stimulation from poorly placed stimulus transducers, 
poorly chosen parameters, and/or limited spatial resolution from a 
given stimulation technology. Increasing the specificity of stimu-
lus delivery to more precisely target the dysfunctional neurons or 
networks should lead to reduced side effect profiles. For DBS, it 
will likely require smaller transducers than current FDA-approved 
DBS electrodes (e.g., microelectrode technology – which may also 
enable VNS devices to more specifically target afferent vagus nerve 
fibers whose activation/inhibition are linked to the purported anti-
depressive benefits). For TMS, increasing the specificity of stimulus 
delivery will require smaller, more-efficient coil designs. After opti-
mizing the specificity of stimulus delivery, waveform optimization 
will be needed to determine the safest, most beneficial parameter 
sets for a given stimulation technology, point of application, and 
patient. Based on more recent findings, biphasic, constant-current 
waveforms should be employed due to their proven safety relative 
to monophasic or constant-voltage waveforms, their enhanced glial 
scar penetration capabilities, and their reversible, charge-balanced 
nature (Albert et al., 2009; Piallat et al., 2009).
QuantIfIable bIologIcal Markers of refractory Mdd
Biomarkers are not currently used in depressive disorder diag-
nostic or treatment paradigms (e.g., Biomarkers are not used 
to confirm the presence of a depressive disorder, quantify its 
relative severity, or to assess treatment compliance/resistance). 
As with stimulation targets, the theories of depressive disorder 
pathogenesis have led to several candidate biomarkers that can 
distinguish normal from depressed patients, treatment compliant 
from   treatment-resistant patients, and non-suicidal from suicidal 
depressed patients (Table 2). However, individual biomarkers have 
not shown sufficient sensitivity and specificity for use in clinical 
practice. A major hurdle preventing the discovery of depressive 
disorder-specific biomarkers is the lack of distinctions between 
MDD patients who share a common set of subjectively defined 
symptoms, but develop the disorder through different circum-
stances. As a result, the upcoming DSM-V and ICD-11 criteria for 
diagnosing MDD may not require biological diagnostic measures 
of MDDs (Mossner et al., 2007).
In light of the current understanding of depressive disorder 
pathogenesis, Mossner et al. (2007) deduced that decreased BDNF 
levels, increased IL-6 levels, reduced folate levels, reduced total 
cholesterol levels, and elevated cortisol levels are among the most 
promising biomarkers for identifying and distinguishing among 
MDDs. Relative to healthy control groups, increased IL-6 (Alesci 
et al., 2005) and decreased BDNF levels (Shimizu et al., 2003) are 
among the most promising biomarkers of depression, decreased 
folate in blood serum is among the most promising biomarkers of 
treatment resistance (Fava et al., 1997), reduced anterior cingulate 
activity is among the most promising biomarkers for predicting 
treatment compliance (Pizzagalli et al., 2001), and decreased total 
cholesterol is among the most promising biomarkers of suicidal 
behavior (Golier et al., 1995; Kunugi et al., 1997). Several researchers 
are investigating the predictive power of abnormal electrical activity 
associated with depression (Tomarken et al., 1992; Pizzagalli et al., 
2001; Garrett et al., 2008). However, progress has been limited, likely 
et al., 2000, 2005). TMS studies typically target the left and/or right 
dorsolateral prefrontal cortex (DLPFC) due to its   accessibility with 
the large stimulation coils and the promising history of its antide-
pressive effects. Slow TMS (sTMS) has only provided antidepressive 
effects when used on the right DLPFC (Klein et al., 1999; Fitzgerald 
et al., 2006), while repetitive/rapid TMS only has provided antide-
pressive effects when used on the left DLPFC (Speer et al., 2000; 
Avery et al., 2006; Fitzgerald et al., 2006). Not surprisingly, DBS 
studies target deep structures such as the subcallosal cingulate gyrus 
(SCG) (Mayberg et al., 2000, 2005; Lozano et al., 2008), ventral cap-
sule/ventral striatum (VC/VS) (Malone et al., 2009), globus pallidus 
internus (GPi) (Kosel et al., 2007), and inferior thalamic peduncle 
(ITP) (Jimenez et al., 2005).
Inconsistent study designs, control/sham selections, stimulation 
parameters, evaluation criteria, and subject selections make it dif-
ficult to compare the reported treatment efficacies of the different 
stimulation technologies and stimulation targets. From Table 1, it 
appears that the most promising stimulation-based antidepres-
sant treatment targets the subcallosal cingulate gyrus white matter 
(SCGwm) using DBS. High-frequency SCGwm stimulation signifi-
cantly reduced symptoms (i.e., Post-treatment HRSD-17 scores were 
50% lower than pre-treatment HRSD-17 scores) in 60% of refrac-
tory MDD patients at 6 months and 55% at 12 months (N = 20) 
(Lozano et al., 2008). The SCG has many pathways that project 
to limbic and paralimbic brain structures, and is likely the most 
important autonomic regulatory region within the frontal cortex 
(Ongur et al., 1998; Davidson et al., 2002). However, due to the 
aforementioned inconsistencies among studies, it is impossible to 
definitively determine which technology is superior at this time.
Each stimulation technology uses different sets of stimulation 
parameters, producing a constant-current- or voltage-based mono- 
or biphasic waveform with a diverse range of amplitudes, pulse 
durations, and stimulation frequencies (see Albert et al., 2009 for 
a comprehensive review of stimulation parameters that have been 
used for VNS, TMS, and DBS). The respective waveforms stimulate 
a target structure continuously or intermittently (in open-loop 
configurations) in hopes of directly or indirectly modulating abnor-
mal activity toward more normal behavior in limbic-associated 
neural pathways and structures (e.g., VNS technology intermit-
tently stimulates for 30 s every 5 min to indirectly modulate brain 
activity via the left cervical vagus nerve, Marangell et al., 2007). 
VNS and DBS stimulation parameters are wirelessly programmed 
approximately 2 weeks after implantation on a patient-specific 
basis. By using patient-reported symptom relief and side effects, 
stimulation pulse duration and amplitude are steadily increased 
over a period of weeks to months (under a constant pulse repeti-
tion frequency) to determine a range of parameters that produce 
the most significant therapeutic benefit with the least side effects 
(monophasic, constant-current stimulation is typically used in VNS 
and monophasic, constant-voltage stimulation is typically used in 
DBS) (Hardesty and Sackeim, 2007).TMS devices first measure a 
patient’s motor threshold (i.e., the magnetic pulse intensity that 
elicits a motor action potential when applied over the motor cor-
tex) before beginning the procedure (Marangell et al., 2007). A 
percentage of the observed motor threshold is then used as the 
baseline intensity at which the magnetic pulse is applied for therapy 
(Albert et al., 2009).Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  9
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with patient-specific depressive symptoms, (4) safely function for 
the duration of a patient’s lifetime without the need for second-
ary surgeries, and (5) store and transmit peri-stimulus biomarker 
responses for off-line analyses. An open-loop system can meet cri-
teria 4–5, but a closed-loop system is needed to meet all five. The 
remainder of Section “Toward Closed-Loop Treatment Options for 
Refractory MDD Patients” first discusses the algorithm require-
ments for autonomously translating abnormal biomarker signals 
into optimized corrective stimuli. It concludes with a closed-loop 
neurostimulation device design framework.
There are two general requirements for an algorithm to autono-
mously optimize closed-loop treatment efficacy. First, an autono-
mous closed-loop optimization algorithm requires a reproducible 
relationship between the applied stimulus parameters and there 
sulting disorder-specific biomarker responses (i.e., The applied 
therapeutic dose of charge and its rate of delivery, using electrical 
stemming from the limitations of using low bandwidth electroen-
cephalograms (EEG) (Pizzagalli et al., 2001) or evoked response 
field potentials (Garrett et al., 2008) to investigate disorders of 
specific neural circuits in deeper brain structures.
toward closed-loop treatMent optIons for 
refractory Mdd patIents
As a last-resort invasive treatment option for refractory MDD 
patients, an implantable neurostimulation device will ideally (1) 
remit depressive symptoms in a predictable, reproducible, and 
quantifiable manner without inducing the variable set of side 
effects observed with current therapies, (2) apply a focal correc-
tive stimulus (i.e., dose of therapy) only when the device confirms 
an impending relapse into a depressive episode, (3) autonomously 
learn and apply the most efficacious corrective stimuli which cor-
rect for differing levels of biomarker abnormalities that correlate 
Table 2 | Promising biomarkers for objectively distinguishing and quantifying depressive states.
Biomarker type  Most promising  Specific testable null  Measurement tools  Special considerationsa 
  marker  hypothesis  and methods
Immune  ↑ IL-6 in serum/plasma  IL IL
dep cont −= − 66   Solid-phase ELISA on  Fluctuating IL-6 level necessitates 
 ( Raison et al.,2006;     extracted plasma  24-h assessment 
  Mossner et al., 2007)    (Alesci et al., 2005)
Endocrine  ↑ Cortisol  cortisolc ortisol
dep cont =   Chemiluminescence-based  Fluctuating cortisol level  
      assay on extracted plasma   neces-sitates 24-h assessment 
     ( Alesci et al., 2005) 
Metabolic  ↓ Blood flow   vv bl,dep bl,cont =   SPECT  Use 99mtechnetium-labeled 
        HMPAO (Martin et al., 2001)
Metabolic  ↓ Glucose  gluc gluc
dep cont =   PET (measure 18F-  Use 18F-fluorodeoxyglucose 
  metabolism    fluorodeoxyglucose  (Brody et al., 2001) 
      metabolism in DLPFC)
Growth and survival  ↓ BDNF in serum  BDNF BDNF
dep cont =   ELISA on extracted serum  Effective AD therapy should 
     ( Karege et al., 2002; Shimizu  restore normal BDNF levels 
     et al., 2003)  (Mossner et al., 2007)
Structural  ↓ Cholesterol  chol chol
dep+suicidal dep =   Cholesterol assay on extracted  Total cholesterol levels are 
      serum (Allain et al., 1974)  significantly lower in suicidal 
        patients (Golier et al., 1995; 
       Kunugi et al., 1997)
Structural/functional  ↓ Folate  folate folate
TRD dep =   Folate assay on extracted  Folate levels are significantly lower 
  in serum   serum (Fava et al., 1997)  in refractory MDDs than in treatable 
        MDDs (Fava et al., 1997;  
       Mossner et al., 2007)
Bioelectric  ↓ Anterior  II AC,dep AC,cont =   Scalp EEG (use 10/10 system  Tomographic analysis necessary to 
  cingulate activity    referenced to left ear) (Pizzagalli  localize current sources (Pascual-Marqui 
     et al., 2001)  et al., 1994; Pizzagalli et al., 2001)
Functional  ↓ 5-HT1A receptor  BP BP dep cont =   PET (measure 5-HT1A  Use [11C]WAY-100635 selective 5-HT1A 
  expression    binding potential)  receptor ligand (Bhagwagar et al., 2004)
Functional  ↓ Imipramine binding  BB max,dep max,cont =   PET (measure Bmax for  Use 3H-imipramine (Raisman et al., 1981) 
  to 5-HTT on platelets    3H-imipramine binding 
 ( Ellis and Salmond, 1994)    in brain tissue)
Unless otherwise specified, information within Table 2 was adapted from Mossner et al. (2007).
AD, antidepressant; BDNF , brain-derived neurotrophic factor; Bmax, maximal affinity binding coefficient; BP , binding potential; ELISA, enzyme-linked immunosorbent 
assay; HMPAO, hexa-methyl propylene-amine-oxime; IL -6, interleukin-6; PET, positron-emission tomography; RN, raphe nucleus; SPECT, single photon emission 
computed tomography; TRD, treatment-resistant depression.
aAt a minimum, control groups must be matched by age, gender, race, and socioeconomic status to accurately represent the general population of refractory 
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biomarker(s) of interest. Over time, a rough relationship between 
the biomarker levels and symptom severity in a particular patient 
can be established. Then, starting with stimulus parameter com-
binations that have shown therapeutic efficacy in other patients, 
the process can be repeated to derive a rough relationship between 
the magnitude/direction of stimulus-associated biomarker abnor-
mality correction and the level of stimulus-associated depressive 
symptom relief. If such relationships are established, investiga-
tors can begin to bridge the knowledge gap that currently exists 
between subjective reports of depressive symptoms and quantifi-
able abnormalities in biomarker levels. With time, the device can 
autonomously fine-tune the most efficacious parameter sets that 
most efficiently lead to the desired outcomes (i.e., minimal dose, 
maximal antidepressant response, minimal side effects, maximal 
antidepressant durability, etc.).
Figure 1 presents a closed-loop device design framework based 
on topics addressed within the review. Figure 1A shows a generic 
closed-loop control system, which runs in parallel to the dysfunc-
tional structure of interest. In each cycle, the four basic processes 
involve (I) measuring the biomarker(s) of interest from the stimula-
tion target or downstream from the stimulation target, (II) com-
paring the measured biomarker levels to non-depressed biomarker 
levels to determine whether a corrective stimulus is needed, (III) 
determining the appropriate set of corrective stimulus parameters 
based on the magnitude of biomarker abnormality and previous 
stimulus/biomarker response data (represented as a multi-dimen-
sional stimulus response surface in Figure 1B), and (IV) applying 
the appropriate corrective stimulus to the stimulation target. This 
generic closed-loop control system design supports any of the alter-
native stimulation-based therapies, accessible stimulation targets, 
and depression-linked biomarkers (refer to Tables 1 and 2).
The  presented  framework  for  designing  depression-specific 
closed-loop devices narrows the design space to a smaller subset 
of promising treatment strategies. In one possible implementation 
(Figure 1B), a DBS electrode array is placed in the SCGwm in order 
to modulate dysfunctional downstream limbic and paralimbic net-
work activity to more “healthy” states when an onboard algorithm 
detects a depressed state (IV). A biosensing microelectrode array (or 
a second DBS electrode array, since these are already FDA-approved, 
Han and McCreery, 2009) is placed downstream from the stimula-
tion target in order to monitor symptom-linked biomarker changes 
in response to the applied stimulus (I, II). Using stored stimulus/
biomarker response data, a stochastic search algorithm is used to 
predict an optimal set of output stimulus parameters that have the 
highest likelihood of correcting for the magnitude of abnormality 
that was detected (III). Many algorithms can accomplish this proc-
ess, such as stochastic search algorithm, genetic algorithm or a clus-
tering algorithm designs, but each will require some form of training 
to maximize sensitivity and specificity for unique applications.
A stochastic search algorithm design called a “Gur Game” can 
in theory optimize stimulation parameters based on a measured 
set of stimulus/biomarker response data from previous stimula-
tions (II–III) (Tung and Kleinrock, 1996; Wong et al., 2008). Such 
an algorithm treats parameters independently, and autonomously 
varies parameters in order to maximize a global response vari-
able (the downstream biomarker response to stimulation, which is 
mapped as a percent of the maximum antidepressant response). The 
stimulation, or the applied drug dose and its rate of delivery, using 
chemical stimulation, should lead to predictable and reproducible 
restorative changes in the observed abnormal biomarker levels). 
Secondly,  an  autonomous  closed-loop  optimization  algorithm 
requires a reproducible relationship between the magnitude and 
direction of biomarker abnormality correction (due the preceding 
applied stimuli) and the level of symptom remission (Behrend et al., 
2009). While the feasibility of the former requirement was recently 
demonstrated (refer to the following paragraph), significant chal-
lenges remain with the latter due to a knowledge gap that remains 
between subjective reports of depressive symptoms and quantifiable 
levels of symptom-linked biomarker abnormality. However, groups 
seeking such knowledge for optimizing treatments in other neuro-
logical disorders have demonstrated promising progress toward this 
end (Wong et al., 2008; Behrend et al., 2009; Smith et al., 2009).
Behrend et al. (2009) successfully demonstrated the feasibility 
of the first of the autonomous closed-loop optimization algorithm 
requirements by using closed-loop STN stimulation to maintain 
defined glutamate levels in the same structure. To do this, a trans-
fer function was first derived to model the relationship between 
randomly patterned high-frequency stimulation pulse trains and 
extracellular glutamate dynamics in rat STN (The investigators 
applied pseudorandom binary sequences of stimulation pulses to 
the STN and used an autoregressive exogenous model to derive the 
transfer function). They found that (1) the derived transfer func-
tion accurately predicts the dynamic glutamate responses to unique 
pulse trains and that (2) on-demand STN stimulation sufficiently 
maintained the desired glutamate levels (i.e., Continuous or pre-
programmed periodic stimulation is not necessary for effective 
control of biomarker levels; the desired biomarker levels in the 
STN can be maintained with on-demand stimulation using pulse 
train patterns with predictable effects on the biomarker level(s)) 
(Behrend et al., 2009). If a predictable and reproducible relationship 
can be established between biomarker abnormality correction and 
depressive symptom relief, then Behrend et al.’s second finding also 
implies that withdrawal of the corrective stimulus will not neces-
sarily lead to a relapse.
To address the feasibility of the second autonomous closed-
loop  optimization  algorithm  requirement,  reproducible  and 
reliable relationships between the magnitude and direction of 
stimulus-  associated  biomarker  abnormality  correction  and 
stimulus-associated depressive symptom relief must be estab-
lished on a patient-to-patient basis. One proposed approach to 
surmounting this barrier is to subjectively assist (i.e., train) the 
treatment-optimization algorithm after the implantation recov-
ery period. For example: after recovering from device implanta-
tion and before turning on the stimulation circuitry, a physician 
can program the device to measure the biomarker(s) of interest 
whenever the patient externally triggers it (e.g., an external piece 
of hardware, such as the wand-like device that a VNS implantee 
uses to externally trigger stimulation (Marangell et al., 2007), can 
be used to wirelessly signal the implanted device to measure the 
biomarker of interest).To subjectively assist the stimulus-optimi-
zation algorithm and provide insight to the physician, the physi-
cian can instruct the patient to routinely assess their depressive 
symptom severity (e.g., using a standardized depression rating 
scale) while simultaneously signaling the device to measure the Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  11
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FiguRe 1 | Proposed closed-loop treatment design framework for 
refractory MDD therapeutics. (A) Generic closed-loop control system. In each 
cycle, the four basic processes involve (I) measuring the biomarker(s) of interest 
from the stimulation target or downstream from the stimulation target, (II) 
comparing the measured biomarker levels to non-depressed biomarker levels in 
order to determine whether a corrective stimulus is needed, (III) determining the 
appropriate set of corrective stimulus parameters based on the magnitude of 
biomarker abnormality and previous stimulus/response data (represented as a 
multi-dimensional stimulus response surface in (B)), and (IV) applying the 
appropriate corrective stimulus. This generic design supports any of the 
alternative stimulation-based therapies, accessible stimulation targets, and 
depression-linked biomarkers (refer to Tables 1 and 2). (B) A proposed 
closed-loop device design framework. Table 1 can be used to find stimulation 
targets that have shown promising treatment efficacy in the refractory MDD 
population (In this example, the SCGwm serves as the stimulation target). 
Table 2 can be used to guide the initial biomarker selection process (in this 
example, downstream single neuron activity is measured using a 
microelectrode array). A charge-balanced, constant-current stimulation 
waveform is used as the corrective stimulus. Pulse width, amplitude, pulse train 
duration, and/or pulse repetition frequency is varied for the next SCGwm 
stimulation based on the type of biomarker abnormality detected and previous 
stimulus/biomarker response data (this data is represented as a multi-
dimensional stimulus response surface). The cycle continues until the maximum 
antidepressant response is achieved.Frontiers in Neuroengineering  www.frontiersin.org  May 2010  | Volume 3  | Article 7  |  12
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